Amputation-free survival after crural percutaneous transluminal angioplasty for critical limb ischemia

Transcription

1 403SJS / Amputation-free survival after crural percutaneous transluminal angioplasty for critical limb ischemiam. Strøm, et al. Original Article Amputation-free survival after crural percutaneous transluminal angioplasty for critical limb ischemia M. Strøm 1,2, L. Konge 2,3, L. Lönn 1,3,4, T. V. Schroeder 2,3, P. Rørdam 1 1 Department of Vascular Surgery, Rigshospitalet, Copenhagen, Denmark 2 Centre for Clinical Education, The Capital Region of Denmark, Copenhagen, Denmark 3 University of Copenhagen, Copenhagen, Denmark 4 Department of Radiology, Rigshospitalet, Copenhagen, Denmark Abstract Background and Aim: To evaluate the amputation-free survival after below the knee percutaneous transluminal angioplasty in a consecutive group of patients with critical ischemia of the lower extremity. Materials and Methods: A total of 70 consecutive patients with critical ischemia were treated with below the knee percutaneous transluminal angioplasty at the vascular center at Rigshospitalet with the purpose of limb salvage. All patients were deemed unfit for major surgery due to anatomical limitations or severe co-morbidity, and no prior attempts of revascularization were performed. Follow-up clinical examinations were performed within 6 weeks and after 1 year. All medical records were crosschecked with the national vascular registry ensuring a valid 1-year status in 97% of the patients. Results: A total of 15 major amputations were performed during follow-up, with 11 amputations performed within the first year. Complications after percutaneous transluminal angioplasty were rare. Cumulative mortality after 1 and 2 years was 22% and 34%, respectively. Amputation-free survival at 1 and 2 years of follow-up was 68% and 58%, respectively. There were no association between known risk factors such as diabetes, ischemic ulcers, cardiac disease, history of smoking, major amputation, or overall amputation. Conclusion: Below the knee percutaneous transluminal angioplasty in patients with endstage peripheral arterial disease and critical limb ischemia is a safe procedure in relieving critical ischemia, reducing the short-term rate of a major amputation as opposed to best medical treatment alone. Key words: Critical limb ischemia; angioplasty; infrapopliteal lesions; survival; amputation Correspondence: Michael Strøm, M.D. Centre for Clinical Education University of Copenhagen and the Capital Region of Denmark Blegdamsvej Copenhagen Denmark michael.stroem@regionh.dk Scandinavian Journal of Surgery 2016, Vol. 105(1) The Finnish Surgical Society 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: / sjs.sagepub.com

2 Amputations-free survival after crural angioplasty 43 Introduction Critical limb ischemia (CLI) is a dangerous condition with a high mortality rate, potential socio-economic loss, and risk of amputation, especially in people with diabetes (1 4). Surgical bypass grafting has long been considered the gold standard of revascularization for lesions that are below the knee (BTK) (5). Percutaneous transluminal angioplasty (PTA) also improves limb perfusion; however, current treatment options are far from optimal even if this endovascular approach is the first-line option for patients with arterial occlusive disease above the inguinal ligament (6 8). In the past, there has been reluctance toward endovascular procedures performed BTK as studies have indicated limited treatment effect (9, 10). Primary patency of BTK angioplasty has shown inferior results at 1-year level compared to peripheral bypass surgery (58% vs 82%); however, the clinical benefit is comparable with equivalent limb salvage rates (11 13). The ultimate goal for treating BTK occlusive disease is to salvage the limb and promote wound healing. Implementing an endovascular first strategy for CLI using low-profile tools suitable for small vessel disease could access even the most challenging calcified arteries (14, 15). Furthermore, sub-intimal technique is also an option for crural arteries (16, 17). Drug-eluting stents (DES) and drug-eluting balloons (DEB) have emerged as potential alternative technologies to combat peripheral arterial disease (PAD) and its risk for restenosis. At present, studies have not convincingly confirmed the added value of these techniques (18, 19). Endovascular intervention of the crural arteries has largely been confined only to patients with CLI and in whom surgical options were limited (20, 21). The aim of this retrospective study was to evaluate limb salvage and survival in BTK arterial segments in patients with critical ischemia following endovascular treatment. Material and methods Patients All patients with CLI who were not eligible for BTK reconstructive vascular surgery were included. This inclusion criterion was determined by an experienced vascular surgeon at the time of referral to PTA. The main reasons for not being a candidate for open surgery are listed in Table 1. In 50% of cases, more than one reason to not consider surgery was present (mean: 1.7; standard deviation (SD): 0.8; range: 1 4). Approval from the regional institutional review board was not required for the performed research. We identified 77 patients having 80 consecutive infrapopliteal endovascular procedures due to CLI from April 2010 through December Data were gathered prospectively from our in-house registry and were analyzed retrospectively. Six patients with prior in situ bypass graft were excluded due to in situ graft stenosis and not stenosis in the genuine artery, as well as one patient who was treated in the aftermath of a trauma and had no history of PAD. Two Table 1 Primary reason for not considering open surgery in the 70 patients included in the series. Technically inoperable a 25 (36%) Severe heart disease 10 (14%) Dementia 8 (11%) Other b 7 (10%) No suitable vein 5 (7%) Sepsis 5 (7%) Location of ulcers 4 (6%) Cancer 2 (3%) Thrombolysis treatment 2 (3%) Immunosuppressive treatment 1 (1%) Severe obesity 1 (1%) a Technically inoperable is defined as no landing zone for a peripheral bypass, receiving artery for peripheral bypass too fragile for anastomosis, or insufficient runoff. b Technically operable, but otherwise judged not fit for operation by a senior consulting vascular surgeon. patients who had bilateral procedures performed were included; however, we excluded the least ischemic limb and only considered the most ischemic leg of each patient. Finally, we included the first treatment of a patient, who had a redo PTA procedure after 3 months, accepting this instance of assisted patency. In total, the series comprised 70 patients receiving 70 infrapopliteal endovascular procedures. Demographic data, preoperative clinical characteristics, endovascular interventions including re-interventions, as well as postoperative characteristics and complications were collected (Table 2). The distribution of the preoperative lesions in the anterior tibial artery, fibular artery, and the posterior tibial artery is presented in Table 2. Vessels were characterized as either open, occluded throughout the artery or with significant stenosis/segmented occlusions. Methods Patient history and available preoperative imaging studies were reviewed by a consultant vascular surgeon and were discussed with a consultant interventional radiologist for consensus. None of the cases suggested peripheral bypass surgery as a viable solution prior to endovascular treatment. In two cases, the result of the crural intervention led to re-evaluation, and subsequent peripheral in situ bypass surgery was performed when the PTA-treated vessels thrombosed 1 and 6 days, respectively, post PTA. Presenting signs of CLI patients were examined with distal pressures measurements and color duplex ultrasound and then referred to angiography for further diagnostics. If angiography and case history indicated no possible means of open surgery in BTK lesions, BTK PTA was performed in the same procedure. The patients were treated with the purpose of limb salvage aimed at recanalizing at least one crural vessel. Treatment of specific angiosomes was not used as indication (22). Standard protocol for intraoperative heparin advised 70IU/kg and additional doses throughout

3 44 M. Strøm, et al. Table 2 Demographic data of 70 patients with critical limb ischemia treated with crural PTA. Age, years 72 (43 93) Median (range) Gender (male) 51 (73%) Acute admission and treatment 44 (63%) Ischemic ulcers 59 (84%) Toe pressure (n = 57) 30 (0 60) mmhg Median (range) Ankle pressure (n = 11) 50 (0 60) mmhg Median (range) History of smoking 38 (54%) Diabetes 50 (71%) Hypertension 44 (63%) Other heart disease 28 (40%) Chronic obstructive pulmonary disease 10 (14%) Endovascular re-intervention 1 (1%) Distribution of 207 lesions in 70 patients Anterior tibial artery 31 (15%) Occluded 39 (19%) Stenosis or segmented occlusion Fibular artery 24 (12%) Occluded 43 (21%) Stenosis or segmented occlusion Posterior tibial artery 46 (22%) Occluded 24 (12%) Stenosis or segmented occlusion Distribution of 103 PTA treatments in 70 patients Anterior tibial artery 36 (35%) Fibular artery 37 (36%) Tibial fibular trunk 10 (10%) Posterior tibial artery 20 (19%) the procedure. In practice, 5000 units were given according to operators discretion followed by 1000 units additionally per hour. Activated clotting time was not included in the standard protocol of the institution. All patients were prescribed statins, and a lifelong 75 mg daily acetylsalicylic acid (ASA) dose was prescribed after the procedure. Clopidogrel was prescribed postoperatively in selected cases (n = 4). The infrapopliteal procedures were performed in a dedicated angiosuite providing high-quality imaging and a large field of view. Vital signs were constantly monitored. The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Standards of Practical Guideline for BTK interventions (23) were followed, including standard low-profile materials of and in, mm PTA balloons up to 240 mm long, and extra long shafts. Both monorail (rapid exchange) and over-the-wire systems were used. Over-the-wire systems create better pushability and column strength and were thus preferred. Long shaft systems up to 150 cm were used when a cross-over approach was deemed necessary. However, the antegrade ipsilateral approach was the preferred choice using an antegrade ultrasound-guided micro-puncture of the common femoral artery (CFA) for access. Baseline digital subtraction angiography (DSA) was obtained from the whole limb using a 4-5 French system. Significant stenoses, defined as 50% diameter reduction as compared to nearest non-diseased segment, of the superficial femoral artery (SFA) were treated primarily with PTA and/or stents. Thereafter, a long sheath/catheter was placed in the popliteal arterial segment and guided by a superselective DSA/roadmap along the crural vessels. Balloon and eventual stent diameters were chosen according to reference vessel diameter by quantitative vessel analysis. Balloon dilatation was up to 2 min, and efforts to treat more than one vessel were observed. Standard angioplasty balloons were used in 64 cases (91%), while DEBs were used in 6 cases (9%) (IN.PACT Amphirion n = 5, IN.PACT Pacific n = 1). No DES or bare metal stents were used in the BTK lesions in this series. In all, 11 patients had simultaneous angioplasty (n = 3) or stenting (Covidien EverFlex n = 5, Abbott Fox n = 2, brand undisclosed n = 1) of the SFA, 1 had an iliac PTA, and 1 patient had a popliteal bailout stenting due to recoil after PTA. Follow-up included clinical examination at 6 weeks and after 1 year. Distal pressure measurements and duplex ultrasound were performed if indicated to the examiners discretion. If patients needed closer observation, the standard regime was subsided by shorter intervals of follow-up. The 1-year data we collected were incomplete (41%); therefore, we crosschecked the medical records with the national records for data on amputation and death at the National Vascular Registry (24) until 1 January This ensured a valid 1-year status of 97% of patients (two patients were lost to follow-up). Amputation-free survival was defined as avoidance of major amputation. Toe, ray, and distal foot amputations were considered minor amputations. Statistics Statistical analysis was performed using SPSS statistical software (SPSS version 19; SPSS, Inc., Chicago, IL, USA). Amputation-free survival and overall survival were evaluated using Kaplan Meier statistics. Association between categorical variables was calculated using Fisher s exact test for small samples. The p-values below 0.01 were considered statistically significant. Results Recanalization of at least one crural artery was obtained in all patients (n = 70). Two or more crural arteries were recanalized in 41% of the cases (n = 29).

4 Amputations-free survival after crural angioplasty 45 Fig. 1. Kaplan Meier curve showing overall survival. Distribution of lesions and treated arteries can be seen in Table 2. One patient (2%) experienced procedure-related complications, developing a groin hematoma demanding surgical evacuation, leading to prolonged wound problems. One patient (2%) presented acute abdomen and respiratory distress suspected of acute mesenteric ischemia, which led to exploratory laparotomy after having peripheral in situ bypass surgery subsequent to endovascular treatment. Two patients died within 30 days (perioperative mortality; 3%) due to toxicity awaiting amputation (n = 1) and cerebral hemorrhage occurring after a minor amputation (n = 1). Two patients were offered peripheral bypass within 30 days of PTA. The first patient had a PTA as a first-line treatment due to severe lesions in all crural vessels and poor runoff, which occluded after 1 week. Peripheral in situ bypass was then performed after surgical exploration of the dorsal pedal artery. The patient suffered severe complications after surgery and died within a year. The second patient had a PTA of the posterior tibial and fibular artery which occluded within a day; therefore, a peripheral in situ bypass was performed to the dorsal pedal artery. The patient remained amputation-free in the observation period. A total of 15 major amputations were performed at a median of 20 months during follow-up (range: 0 41). In all, 11 were performed within the first year. A total of 21 minor amputations were reported, with 8 performed prior to revascularization. All patients had at least two diseased crural vessels. In all, 207 crural arteries were diseased, and in the 70 procedures, 103 BTK PTA treatments were performed. Cumulative mortality after 1 and 2 years was 22% and 34%, respectively (Fig. 1). Amputation-free survival at 1 and 2 years of follow-up was 68% and 58%, respectively (Fig. 2). Mortality at 1 year among major amputees was 36% and among non-amputees (n.s.) was 19%. We found no significant association between amputation regardless of location (both major and minor) and death at 1-year level (p = 0.044). No association was found between diabetes, ischemic ulcers, cardiac disease, and history of smoking versus major amputation or overall amputation (Table 3). Furthermore, we found no significant association between outcome and number of treated arteries, nor which arteries were treated. Discussion The present series demonstrated the clinical outcome after crural angioplasty in patients with CLI. Outcomes were based on hard endpoints, that is, death and amputation since patency was not investigated systematically. Complications were infrequent, with only one instance that was directly associated with the endovascular procedure. This confirms the low complication rate reported in the literature (15). Critical ischemia is associated with a general poor prognosis for limb salvage and life expectancy. All patients with peripheral artery disease should be given statins and a platelet inhibitor. If intolerant to ASA, clopidogrel is

5 46 M. Strøm, et al. Fig. 2. Kaplan Meier curve showing major amputation-free survival. Table 3 Association between co-morbidity and event before 1 year from intervention. Major amputation Overall amputation Death Death or amputation Smoker p = 1.0 p = 1.0 p = 0.4 p = 1.0 Diabetes p = 1.0 p = 0.4 p = 0.8 p = 1.0 Hypertension p = 0.7 p = 0.1 p = 1.0 p = 0.8 Cardiac disease p = 0.7 p = 0.8 p = 0.1 p = 0.1 COPD p = 0.6 p = 0.7 p = 0.2 p = 0.3 Ischemic ulcers p = 0.7 p = 0.1 p = 0.4 p = 1.0 Mortality 1 year p = 0.2 p = 0.04 advised. There is no solid evidence to guide the level of choice between platelet inhibitors. All patients in the series were medicated according to this protocol. The 1-year amputation-free survival in patients with critical ischemia receiving conservative treatment is only 51% (25, 26). In this study, intervention was aimed at reducing the level of ischemia in order to avoid major amputation. The obtained 1-year amputation-free survival of 68% is superior to best medical treatment only (19, 25). In contrast, peripheral bypass surgery in patients with critical ischemia indicated an amputation-free survival rate after 5 years of over 80% (7). Peripheral bypass was not a viable option in our study; therefore, a direct evaluation of PTA first strategy and a surgery later strategy was not feasible. In the two cases where peripheral bypass were performed, the cases were re-evaluated when the PTAtreated artery occluded and a new decision was made to try surgery. The risk of amputation increases according to the severity of crural lesions (27). We found no association between the number of recanalized crural vessels and amputation-free survival nor were crural interventions associated with amputations alone. These findings are not unexpected considering the modest sample size and heterogeneity of the patients. The 1-year mortality rate of 22% is in line with the current literature. This high mortality, as well as the association between overall amputation and death at 1 year, indicates the severity of CLI. Endovascular attempt was initiated under consideration that the risk superseded the possible gain of the open surgical procedure (28). Freedom from amputation after 1 year is as high as 84% in the current literature (11, 29). However, most studies evaluate patients receiving subsequent treatment in order to keep the reconstruction patent. The freedom from re-intervention is described as low as 54%. In our series, only one re-intervention was performed and two peripheral bypasses were attempted. Our population comprised patients in whom the ischemia was advanced to a degree where 11% had minor amputations performed prior to revascularization. The 1-year mortality in our study was expected and in line with the current literature. The long-term efficiency could not be evaluated at present time due to the short follow-up time.

6 Amputations-free survival after crural angioplasty 47 We have presented a small retrospective single center study, and the results are thus limited. The follow-up period is short, but as last resort of intervention in severely ill patients, the primary goal was to investigate short-term outcome. Results are compared to literature as we have no comparator group. At our facility, patients without the possibility of vascular intervention are referred to either local orthopedic department or a specialized wound department for further treatment, and follow-up is terminated. In the same period, 114 BTK peripheral bypasses were performed. However, comparing the outcome of these patients to our study group would possibly be confounded due to discrepancy in morbidity and severity of lesions. Furthermore, while all patients with CLI will not be suffering major amputation, selecting the ones who will without intervention can be daunting, and it would be an ethical challenge to undertake a randomized study of intervention versus best medical treatment, when means of treatment are available. To further investigate the effect of BTK PTA, we suggest a prospective study with a longer follow-up period including data on wound healing, lesion size, site, endovascular tool (DEB vs non-deb), and assisted patency. To show an increase in 1-year amputationfree survival from 70% to 80%, we suggest a multicenter effort as power analysis necessitates nearly 600 patients for randomization. Conclusion We found a 1-year major amputation-free survival of 68% and cumulative 1-year mortality of 22% in a group of patients with CLI who were not eligible for open vascular surgery. For patients with end-stage PAD and CLI, who are not fit for surgery, BTK PTA is a safe procedure in relieving critical ischemia, reducing the short-term rate of a major amputation as opposed to best medical treatment alone. Declaration of conflicting interests The authors declares that there is no conflict of interest Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. References 1. Atar E, Siegel Y, Avrahami R et al: Balloon angioplasty of popliteal and crural arteries in elderly with critical chronic limb ischemia. Eur J Radiol 2005;53(2): Inan B, Aydin U, Ugurlucan M et al: Surgical treatment of lower limb ischemia in diabetic patients Long-term results. Arch Med Sci 2013;9(6): Faglia E, Clerici G, Clerissi J et al: Early and five-year amputation and survival rate of diabetic patients with critical limb ischemia: Data of a cohort study of 564 patients. Eur J Vasc Endovasc Surg 2006;32(5): Peeters P, Verbist J, Keirse K et al: Endovascular procedures and new insights in diabetic limb salvage. J Cardiovasc Surg 2012;53(1): Söderström MI, Arvela EM, Korhonen M et al: Infrapopliteal percutaneous transluminal angioplasty versus bypass surgery as first-line strategies in critical leg ischemia: A propensity score analysis. Ann Surg 2010;252(5): Baumann F, Willenberg T, Do D-D et al: Endovascular revascularization of below-the-knee arteries: Prospective shortterm angiographic and clinical follow-up. J Vasc Interv Radiol 2011;22(12): Conrad MF, Crawford RS, Hackney LA et al: Endovascular management of patients with critical limb ischemia. J Vasc Surg 2011;53(4): Varcoe RL: Drug eluting stents in the treatment of below the knee arterial occlusive disease. J Cardiovasc Surg 2013;54(3): Sigala F, Kontis E, Hepp W et al: Long-term outcomes following 282 consecutive cases of infrapopliteal PTA and association of risk factors with primary patency and limb salvage. Vasc Endovascular Surg 2012;46(2): Fanelli F, Cannavale A: Endovascular treatment of infrapopliteal arteries: Angioplasty vs stent in the drug-eluting era. Eur Radiol 2014;24(4): Romiti M, Albers M, Brochado-Neto FC et al: Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg 2008;47(5): Ferraresi R, Centola M, Ferlini M et al: Long-term outcomes after angioplasty of isolated, below-the-knee arteries in diabetic patients with critical limb ischaemia. Eur J Vasc Endovasc Surg 2009;37(3): Baumann F, Diehm N: Restenosis after infrapopliteal angioplasty Clinical importance, study update and further directions. Vasa 2013;42(6): Christensen J, Andersen PE: Diabetic foot-artery intervention below the knee. Ugeskr Laeger 2013;175(12):795. (In Danish) 15. Krankenberg H, Sorge I, Zeller T et al: Percutaneous transluminal angioplasty of infrapopliteal arteries in patients with intermittent claudication: Acute and one-year results. Catheter Cardiovasc Interv 2005;64(1): Met R, Van Lienden KP, Koelemay MJW et al: Subintimal angioplasty for peripheral arterial occlusive disease: A systematic review. Cardiovasc Intervent Radiol 2008;31(4): Ingle H, Nasim A, Bolia A et al: Subintimal angioplasty of isolated infragenicular vessels in lower limb ischemia: Long-term results. J Endovasc Ther 2002;9(4): Rastan A, Noory E, Zeller T: Drug-eluting stents for treatment of focal infrapopliteal lesions. Vasa 2012;41(2): Jens S, Conijn AP, Koelemay MJW et al: Randomized trials for endovascular treatment of infrainguinal arterial disease: Systematic review and meta-analysis (Part 2: Below the knee). Eur J Vasc Endovasc Surg 2014;47(5): Beard JD: Which is the best revascularization for critical limb ischemia: Endovascular or open surgery? J Vasc Surg 2008;48(6 Suppl.):11S 16S. 21. Gasper WJ, Runge SJ, Owens CD: Management of infrapopliteal peripheral arterial occlusive disease. Curr Treat Options Cardiovasc Med 2012;14(2): Taylor GI, Palmer JH: The vascular territories (angiosomes) of the body: Experimental study and clinical applications. Br J Plast Surg 1987;40(2): Van Overhagen H, Spiliopoulos S, Tsetis D: Below-the-knee interventions. Cardiovasc Intervent Radiol 2013;36(2): Karbase The Danish Vascular Registry [Internet], Kret MR, Perrone KH, Azarbal AF et al: Medical comorbidities but not interventions adversely affect survival in patients with intermittent claudication. J Vasc Surg 2013;58(6): Biancari F: Meta-analysis of the prevalence, incidence and natural history of critical limb ischemia. J Cardiovasc Surg 2013;54(6): Faglia E, Clerici G, Clerissi J et al: When is a technically successful peripheral angioplasty effective in preventing abovethe-ankle amputation in diabetic patients with critical limb ischaemia? Diabet Med 2007;24(8):

7 48 M. Strøm, et al. 28. Revenig LM, Canter DJ, Taylor MD et al: Too frail for surgery? Initial results of a large multidisciplinary prospective study examining preoperative variables predictive of poor surgical outcomes. J Am Coll Surg 2013;217(4): e Giles KA, Pomposelli FB, Spence TL et al: Infrapopliteal angioplasty for critical limb ischemia: Relation of TransAtlantic InterSociety Consensus class to outcome in 176 limbs. J Vasc Surg 2008;48(1): Received: October 22, 2014 Accepted: January 12, 2015